Loading...
•
Dec 31, 2024
Globus Medical Q4 2024 Earnings Report
Globus Medical reported strong revenue growth in Q4 2024, driven by the NuVasive acquisition and increased sales of spine products and enabling technology.
Key Takeaways
Globus Medical achieved Q4 2024 revenue of $657.3 million, reflecting a 6.6% increase year-over-year. GAAP net income reached $26.5 million, while non-GAAP net income stood at $117.4 million. Non-GAAP diluted EPS was $0.84, marking a 35.7% improvement from Q4 2023. The company's U.S. sales grew by 6.3%, while international sales increased by 7.7%.
Q4 2024 revenue increased by 6.6% year-over-year to $657.3 million.
GAAP net income surged 76.3% to $26.5 million.
Non-GAAP diluted EPS rose 35.7% to $0.84.
International revenue growth outpaced U.S. sales with an 8.9% increase on a constant currency basis.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Globus Medical reaffirms its 2025 revenue guidance of $2.66B to $2.69B, with expected non-GAAP EPS between $3.40 and $3.50. Following the anticipated Nevro acquisition, full-year revenue is projected to reach $2.80B to $2.90B, with non-GAAP EPS of $3.10 to $3.40.
Positive Outlook
- Expected revenue growth to $2.66B-$2.69B in 2025.
- Non-GAAP EPS guidance set between $3.40-$3.50.
- Further revenue increase expected post-Nevro acquisition.
- Continued operational efficiencies and cost management focus.
- Ongoing investment in innovation and spine technology solutions.
Challenges Ahead
- Potential integration challenges with Nevro acquisition.
- Foreign currency fluctuations may impact financial results.
- Increased competition in the musculoskeletal technology market.
- Macroeconomic uncertainties could affect demand.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...